{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:00:11Z","timestamp":1790470811292,"version":"4.1.0"},"reference-count":54,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2020.0513","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T14:19:06Z","timestamp":1594304346000},"source":"Crossref","is-referenced-by-count":132,"title":["The Diagnosis and Treatment of Age-Related Macular Degeneration"],"prefix":"10.3238","author":[{"given":"Andreas","family":"Stahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"10.3238\/arztebl.2020.0513_ref1","doi-asserted-by":"crossref","unstructured":"Bourne RRA, Jonas JB, Flaxman SR, et al.: Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990\u20132010. Br J Ophthalmol 2014; 98: 629\u201338","DOI":"10.1136\/bjophthalmol-2013-304033"},{"key":"10.3238\/arztebl.2020.0513_ref2","doi-asserted-by":"crossref","unstructured":"Wong WL, Su X, Li X, et al.: Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2: e106\u201316","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"10.3238\/arztebl.2020.0513_ref3","doi-asserted-by":"crossref","unstructured":"Korb CA, Kottler UB, Wolfram C, et al.: Prevalence of age-related macular degeneration in a large European cohort: results from the population-based Gutenberg Health Study. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1403\u201311","DOI":"10.1007\/s00417-014-2591-9"},{"key":"10.3238\/arztebl.2020.0513_ref4","doi-asserted-by":"crossref","unstructured":"Brandl C, Breinlich V, Stark KJ, et al.: Features of age-related macular degeneration in the general adults and their dependency on age, sex, and smoking: results from the German KORA Study. PLoS ONE 2016; 11: e0167181","DOI":"10.1371\/journal.pone.0167181"},{"key":"10.3238\/arztebl.2020.0513_ref5","doi-asserted-by":"crossref","unstructured":"Brandl C, Zimmermann ME, G\u00fcnther F, et al.: On the impact of different approaches to classify age-related macular degeneration: results from the German AugUR study. Sci Rep 2018; 8: 8675","DOI":"10.1038\/s41598-018-26629-5"},{"key":"10.3238\/arztebl.2020.0513_ref6","doi-asserted-by":"crossref","unstructured":"Schuster AK, Wolfram C, Pfeiffer N, Finger RP: Ophthalmology 2019-where do we stand?: an analysis of the treatment situation in Germany. Ophthalmologe 2019; 116: 829\u201337","DOI":"10.1007\/s00347-019-0894-2"},{"key":"10.3238\/arztebl.2020.0513_ref7","doi-asserted-by":"crossref","unstructured":"Finger RP, Bertram B, Wolfram C, Holz FG. Blindness and visual impairment in Germany: a slight fall in prevalence. Dtsch Arztebl Int 2012; 109: 484\u20139","DOI":"10.3238\/arztebl.2012.0484"},{"key":"10.3238\/arztebl.2020.0513_ref8","doi-asserted-by":"crossref","unstructured":"Mauschitz MM, Li JQ, Larsen PP, et al.: Epidemiology of severe visual impairment and blindness of old people in Germany. Ophthalmologe 2019; 116: 201\u201312","DOI":"10.1007\/s00347-019-0853-y"},{"key":"10.3238\/arztebl.2020.0513_ref9","doi-asserted-by":"crossref","unstructured":"Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP: Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol 2019; bjophthalmol-2019\u2013314422","DOI":"10.1136\/bjophthalmol-2019-314422"},{"key":"10.3238\/arztebl.2020.0513_ref10","doi-asserted-by":"crossref","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, et al.: Prevalence of age-related macular degeneration in Europe: The past and the future. Ophthalmology 2017; 124: 1753\u201363","DOI":"10.1016\/j.ophtha.2017.05.035"},{"key":"10.3238\/arztebl.2020.0513_ref11","doi-asserted-by":"crossref","unstructured":"Wilde C, Poostchi A, Mehta RL, et al.: Prevalence of age-related macular degeneration in an elderly UK Caucasian population-The Bridlington Eye Assessment Project: a cross-sectional study. Eye (Lond) 2017; 31: 1042\u201350","DOI":"10.1038\/eye.2017.30"},{"key":"10.3238\/arztebl.2020.0513_ref12","doi-asserted-by":"crossref","unstructured":"Joachim N, Colijn JM, Kifley A, et al.: Five-year progression of unilateral age-related macular degeneration to bilateral involvement: the Three Continent AMD Consortium report. Br J Ophthalmol 2017; 101: 1185\u201392","DOI":"10.1136\/bjophthalmol-2016-309729"},{"key":"10.3238\/arztebl.2020.0513_ref13","doi-asserted-by":"crossref","unstructured":"Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417\u201336","DOI":"10.1001\/archopht.119.10.1417"},{"key":"10.3238\/arztebl.2020.0513_ref14","doi-asserted-by":"crossref","unstructured":"Keenan TD, Agr\u00f3n E, Domalpally A, et al.: Progression of geographic atrophy in age-related macular degeneration: AREDS2 Report Number 16. Ophthalmology 2018; 125: 1913\u201328","DOI":"10.1016\/j.ophtha.2018.05.028"},{"key":"10.3238\/arztebl.2020.0513_ref15","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419\u201331","DOI":"10.1056\/NEJMoa054481"},{"key":"10.3238\/arztebl.2020.0513_ref16","doi-asserted-by":"crossref","unstructured":"Chakravarthy U, Augood C, Bentham GC, et al.: Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology 2007; 114: 1157\u201363","DOI":"10.1016\/j.ophtha.2006.09.022"},{"key":"10.3238\/arztebl.2020.0513_ref17","doi-asserted-by":"crossref","unstructured":"Klein RJ, Zeiss C, Chew EY, et al.: Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385\u20139","DOI":"10.1126\/science.1109557"},{"key":"10.3238\/arztebl.2020.0513_ref18","doi-asserted-by":"crossref","unstructured":"Hageman GS, Anderson DH, Johnson LV, et al.: A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227\u201332","DOI":"10.1073\/pnas.0501536102"},{"key":"10.3238\/arztebl.2020.0513_ref19","doi-asserted-by":"crossref","unstructured":"Rivera A, Fisher SA, Fritsche LG, et al.: Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005; 14: 3227\u201336","DOI":"10.1093\/hmg\/ddi353"},{"key":"10.3238\/arztebl.2020.0513_ref20","doi-asserted-by":"crossref","unstructured":"Kanda A, Chen W, Othman M, et al.: A variant of mitochondrial protein LOC387715\/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA 2007; 104: 16227\u201332","DOI":"10.1073\/pnas.0703933104"},{"key":"10.3238\/arztebl.2020.0513_ref21","doi-asserted-by":"crossref","unstructured":"Gibson J, Cree A, Collins A, Lotery A, Ennis S: Determination of a gene and environment risk model for age-related macular degeneration. Br J Ophthalmol 2010; 94:1382\u20137 CrossRef","DOI":"10.1136\/bjo.2010.182568"},{"key":"10.3238\/arztebl.2020.0513_ref22","doi-asserted-by":"crossref","unstructured":"Brown CN, Green BD, Thompson RB, den Hollander AI, Lengyel I, EYE-RISK consortium: Metabolomics and age-related macular degeneration. Metabolites 2018; 9: 4","DOI":"10.3390\/metabo9010004"},{"key":"10.3238\/arztebl.2020.0513_ref23","unstructured":"Deutsche Ophthalmologische Gesellschaft (DOG): Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany \u2013 November 2014. Ophthalmologe 2015; 112: 237\u201345."},{"key":"10.3238\/arztebl.2020.0513_ref24","doi-asserted-by":"crossref","unstructured":"Berufsverband der Augen\u00e4rzte Deutschlands e. V., Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft e. V.: Quality assurance of optical coherence tomography for diagnostics of the fundus: positional statement of the BVA, DOG and RG. Ophthalmologe 2017; 114: 617\u201324.","DOI":"10.1007\/s00347-017-0508-9"},{"key":"10.3238\/arztebl.2020.0513_ref25","doi-asserted-by":"crossref","unstructured":"Velilla S, Garc\u00eda-Medina JJ, Garc\u00eda-Layana A, et al.: Smoking and age-related macular degeneration: review and update. J Ophthalmol 2013; 2013: 895147","DOI":"10.1155\/2013\/895147"},{"key":"10.3238\/arztebl.2020.0513_ref26","doi-asserted-by":"crossref","unstructured":"Lee S, Song SJ, Yu HG: Current smoking is associated with a poor visual acuity improvement after intravitreal ranibizumab therapy in patients with exudative age-related macular degeneration. J Korean Med Sci 2013; 28: 769\u201374","DOI":"10.3346\/jkms.2013.28.5.769"},{"key":"10.3238\/arztebl.2020.0513_ref27","doi-asserted-by":"crossref","unstructured":"Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005\u201315","DOI":"10.1001\/jama.2013.4997"},{"key":"10.3238\/arztebl.2020.0513_ref28","unstructured":"Deutsche Ophthalmologische Gesellschaft: Supplements in age-related macular degeneration: recommendations by the German Ophthalmological Society, the German Retina Society and the German Professional Association of Ophthalmologists. Ophthalmologe 2015; 112: 35\u201340."},{"key":"10.3238\/arztebl.2020.0513_ref29","doi-asserted-by":"crossref","unstructured":"Merle BMJ, Colijn JM, Cougnard-Gr\u00e9goire A, et al.: Mediterranean diet and incidence of advanced age-related macular degeneration: The EYE-RISK Consortium. Ophthalmology 2019; 126: 381\u201390","DOI":"10.1016\/j.ophtha.2018.08.006"},{"key":"10.3238\/arztebl.2020.0513_ref30","doi-asserted-by":"crossref","unstructured":"Ferris FL, Wilkinson CP, Bird A, et al.: Clinical classification of age-related macular degeneration. Ophthalmology 2013; 120: 844\u201351","DOI":"10.1016\/j.ophtha.2012.10.036"},{"key":"10.3238\/arztebl.2020.0513_ref31","doi-asserted-by":"crossref","unstructured":"Guymer RH, Wu Z, Hodgson LAB, et al.: Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD randomized controlled clinical trial. Ophthalmology 2019; 126: 829\u201338","DOI":"10.1016\/j.ophtha.2019.07.016"},{"key":"10.3238\/arztebl.2020.0513_ref32","doi-asserted-by":"crossref","unstructured":"Berufsverband der Augen\u00e4rzte Deutschlands e. V., (BVA), Deutsche Ophthalmologische Gesellschaft, (DOG), Retinologische Gesellschaft e. V., (RG): Statement and supplementary statement from the BVA, the DOG, and the RG on laser treatment of drusen in age-related macular degeneration (AMD): August 2017, update October 2018. Ophthalmologe 2020; 117: 1\u201310","DOI":"10.1007\/s00347-019-0889-z"},{"key":"10.3238\/arztebl.2020.0513_ref33","doi-asserted-by":"crossref","unstructured":"Holz FG, Sadda SR, Busbee B, et al.: Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol 2018; 136: 666\u201377","DOI":"10.1001\/jamaophthalmol.2018.1544"},{"key":"10.3238\/arztebl.2020.0513_ref34","doi-asserted-by":"crossref","unstructured":"Bloch SB, Larsen M, Munch IC: Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153: 209\u2013213","DOI":"10.1016\/j.ajo.2011.10.016"},{"key":"10.3238\/arztebl.2020.0513_ref35","doi-asserted-by":"crossref","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331\u20135","DOI":"10.3928\/1542-8877-20050701-14"},{"key":"10.3238\/arztebl.2020.0513_ref36","doi-asserted-by":"crossref","unstructured":"Chandra S, Arpa C, Menon D, et al.: Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. Eye (Lond) 2020; (epub ahead of print","DOI":"10.1038\/s41433-020-01386-w"},{"key":"10.3238\/arztebl.2020.0513_ref37","doi-asserted-by":"crossref","unstructured":"CATT Research Group, Martin DF, Maguire MG, et al.: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897\u2013908","DOI":"10.1056\/NEJMoa1102673"},{"key":"10.3238\/arztebl.2020.0513_ref38","doi-asserted-by":"crossref","unstructured":"Wecker T, Grundel B, Reichl S, et al.: Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment. Sci Rep 2019; 9: 3301","DOI":"10.1038\/s41598-019-38934-8"},{"key":"10.3238\/arztebl.2020.0513_ref39","doi-asserted-by":"crossref","unstructured":"Holz FG, Tadayoni R, Beatty S, et al.: Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 2016; 100: 1623\u20138","DOI":"10.1136\/bjophthalmol-2015-308166"},{"key":"10.3238\/arztebl.2020.0513_ref40","doi-asserted-by":"crossref","unstructured":"Wecker T, Ehlken C, B\u00fchler A, et al.: Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 2017; 101: 353\u20139","DOI":"10.1136\/bjophthalmol-2016-308668"},{"key":"10.3238\/arztebl.2020.0513_ref41","doi-asserted-by":"crossref","unstructured":"Spraul CW, Lang GE, Grossniklaus HE, Lang GK: Histologic and morphometric analysis of the choroid, Bruch\u2019s membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol 1999; 44: S10\u201332","DOI":"10.1016\/S0039-6257(99)00086-7"},{"key":"10.3238\/arztebl.2020.0513_ref42","doi-asserted-by":"crossref","unstructured":"Curcio CA: Antecedents of soft drusen, the specific deposits of age-related macular degeneration, in the biology of human macula. Invest Ophthalmol Vis Sci 2018; 59: AMD182\u201394","DOI":"10.1167\/iovs.18-24883"},{"key":"10.3238\/arztebl.2020.0513_ref43","doi-asserted-by":"crossref","unstructured":"Yoo TK, Kim SH, Kwak J, Kim HK, Rim TH: Association between osteoporosis and age-related macular degeneration: The Korea National Health and Nutrition Examination Survey. Invest Ophthalmol Vis Sci 2018; 59: AMD132\u201342","DOI":"10.1167\/iovs.18-24059"},{"key":"10.3238\/arztebl.2020.0513_ref44","doi-asserted-by":"crossref","unstructured":"Chakravarthy U, Wong TY, Fletcher A, et al.: Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31","DOI":"10.1186\/1471-2415-10-31"},{"key":"10.3238\/arztebl.2020.0513_ref45","doi-asserted-by":"crossref","unstructured":"van Leeuwen EM, Emri E, Merle BMJ, et al.: A new perspective on lipid research in age-related macular degeneration. Prog Retin Eye Res 2018; 67: 56\u201386","DOI":"10.1016\/j.preteyeres.2018.04.006"},{"key":"10.3238\/arztebl.2020.0513_ref46","doi-asserted-by":"crossref","unstructured":"Pennington KL, DeAngelis MM: Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond) 2016; 3: 34","DOI":"10.1186\/s40662-016-0063-5"},{"key":"10.3238\/arztebl.2020.0513_ref47","doi-asserted-by":"crossref","unstructured":"Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029\u201335","DOI":"10.1056\/NEJM199404143301501"},{"key":"10.3238\/arztebl.2020.0513_ref48","doi-asserted-by":"crossref","unstructured":"Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150\u20135","DOI":"10.1056\/NEJM199605023341802"},{"key":"10.3238\/arztebl.2020.0513_ref49","doi-asserted-by":"crossref","unstructured":"Evans JR, Lawrenson JG: A review of the evidence for dietary interventions in preventing or slowing the progression of age-related macular degeneration. Ophthalmic Physiol Opt 2014; 34: 390\u20136","DOI":"10.1111\/opo.12142"},{"key":"10.3238\/arztebl.2020.0513_ref50","doi-asserted-by":"crossref","unstructured":"Breakthrough of the year: The Runners-Up. Science 2006; 314: 1850\u20135","DOI":"10.1126\/science.314.5807.1850a"},{"key":"10.3238\/arztebl.2020.0513_ref51","doi-asserted-by":"crossref","unstructured":"Merani R, Hunyor AP: Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retina Vitreous 2015; 1: 9","DOI":"10.1186\/s40942-015-0010-y"},{"key":"10.3238\/arztebl.2020.0513_ref52","doi-asserted-by":"crossref","unstructured":"Relhan N, Forster RK, Flynn HW: Endophthalmitis: then and now. Am J Ophthalmol 2018; 187: xx\u2013xxvii","DOI":"10.1016\/j.ajo.2017.11.021"},{"key":"10.3238\/arztebl.2020.0513_ref53","doi-asserted-by":"crossref","unstructured":"Tolentino M: Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56: 95\u2013113","DOI":"10.1016\/j.survophthal.2010.08.006"},{"key":"10.3238\/arztebl.2020.0513_ref54","doi-asserted-by":"crossref","unstructured":"Meyer CH, Michels S, Rodrigues EB, et al.: Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 2011; 89: 70\u20135","DOI":"10.1111\/j.1755-3768.2010.02064.x"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2020.0513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T05:14:41Z","timestamp":1638767681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2020.0513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":54,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2020.0513","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]}}}